Gad Perry profile picture

Contact Information

Gad Perry, MD,FRCPC
613-737-7700 ext 25395

Gad Perry

Clinician Investigator, Cancer Therapeutics Program
Ottawa Hospital Research Institute

Research Interests

Prostate cancer radiation treatment, Lung cancer radiation treatment, Prostate brachytherapy.

Brief Biography

Dr. Gad Perry is a radiation oncologist at the Ottawa Hospital Cancer Centre and a clinical investigator with OHRI. He received his medical degree from UOttawa in 1985, and finished his Radiation Oncology residency in 1995. His areas of specialty include genito-urinary cancers, lung cancers and brachytherapy.
He is the head of the Ottawa Brachytherapy Programme.

Selected Publications

Real-time measurement of urethral dose and position during permanent seed implantation for prostate brachytherapy. Cherpak A, Cygler J, E C, Perry G. Brachytherapy Journal 2014 Mar-Apr;13(2):169-77

A phase III trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases. Sperduto Paul W, Wang Meihua, Robins H. Ian, Schell Michael C, Werner-Wasik Maria, Komaki Ritsuko U, Souhami Luis, Buyounouski Mark K, Khuntia Deepak, Demas William F, Shah Sunjay A, Nedzi Lucien A, Perry GA, Suh John H, Mehta Minesh H.  International Journal of Radiation Oncology Biology Physics. 2013 April 1; 85(5):1312-1318

Twenty-four-month post radiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Crook JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, Ludgate C, Fung S, Lockwood G. Cancer. 2009 Feb 1; 115(3):673-9.

Final report of a multicenter Canadian phase III randomized trial of 3 months vs.8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. International Journal of Radiation Oncology Biology Physics. 2009 Feb 1;73(2):327-33.

Feasibility study of using MOSFET detectors for in-vivo dosimetry during permanent low-dose-rate prostate implants. Cygler J, Saoudi A, Perry G, Morash C, E C. Radiotherapy and Oncology 2006; 80(3):296-301.